What Are Peptides? Types, Benefits, and Uses in Medicine

What Peptides Actually Are

A peptide is a molecule built from two or more amino acids joined by peptide bonds. That sounds like chemistry-class material, but the practical point is simpler: peptides are the body's short-form messaging system. They tell cells to release hormones, repair tissue, regulate appetite, and modulate inflammation, among dozens of other jobs.

The distinction between a peptide and a protein is mostly size. Fewer than 50 amino acids is generally called a peptide; more than that becomes a protein, though the boundary is blurry in practice. Insulin, for example, is technically a small protein at 51 residues, yet it is often discussed alongside peptide drugs because it shares the same class of signaling biology.

Your body makes thousands of endogenous peptides. Oxytocin, the hormone that surges during childbirth and breastfeeding, is a 9-amino-acid peptide. Glucagon-like peptide-1 (GLP-1), the gut hormone behind the current wave of weight-loss drugs, is a 30-amino-acid peptide. Gonadotropin-releasing hormone (GnRH), which sits at the top of the entire reproductive hormone cascade, is a 10-amino-acid peptide.

Why Peptides Matter Differently for Women

Women's biology is not a small-man variant. Sex hormones, including estrogen and progesterone, directly regulate how peptide receptors are expressed, how quickly peptides are cleared from circulation, and how strongly cells respond to a given signal. Research published in Endocrinology showed that estrogen upregulates GLP-1 receptor expression in the pancreas and brain, which partly explains why premenopausal women and women on estrogen therapy show different metabolic responses to GLP-1 drugs than men do.

This is not a minor footnote. It affects dosing, side effects, and which life stage gets the most benefit from any given peptide-based treatment.

The Main Categories of Therapeutic Peptides

1. Hormone-Mimicking Peptides

These replicate or modify hormones the body already makes.

GLP-1 receptor agonists are the most discussed right now. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are synthetic analogs of gut-derived peptides that slow gastric emptying, reduce appetite, and improve insulin sensitivity. In the STEP 1 trial, semaglutide 2.4 mg weekly produced a mean 14.9% reduction in body weight over 68 weeks in adults with obesity or overweight.

Insulin remains the most prescribed therapeutic peptide globally. All current insulin products are synthetic or biosynthetic peptides modeled on endogenous human insulin.

Oxytocin (Pitocin) is used in obstetrics to induce or augment labor and to control postpartum hemorrhage. It is an endogenous peptide that becomes critically relevant at the moment of delivery.

Leuprolide (Lupron) is a GnRH agonist used in endometriosis, uterine fibroids, and fertility protocols. It suppresses ovarian hormone production by desensitizing pituitary GnRH receptors.

2. Antimicrobial Peptides

The immune system uses peptides called defensins as a first-line defense against bacteria, fungi, and viruses. Pharmaceutical antimicrobial peptides, such as vancomycin analogs and polymyxins, are used for resistant infections. This category is mostly relevant to infectious disease medicine rather than women's outpatient care, though vaginal defensin levels drop after menopause, which contributes to the increased risk of urinary tract infections in postmenopausal women.

3. Structural and Repair Peptides

BPC-157 (body protection compound) is a synthetic 15-amino-acid peptide derived from a gastric protein. It circulates in fitness and longevity spaces as a "healing" compound. Animal studies show it may accelerate tendon and gut healing, but no completed, peer-reviewed human clinical trials have established safety or efficacy in women or men. The FDA has not approved it for any indication, and compounding pharmacies have faced regulatory warnings about its use.

Collagen peptides sold as oral supplements are hydrolyzed proteins broken into short amino acid chains. A 12-week randomized controlled trial in the Journal of Cosmetic Dermatology found modest improvements in skin elasticity in women aged 35 and older. The effect size is real but small, and the mechanism is indirect, since ingested peptides are digested rather than absorbed intact.

4. Bone-Active Peptides

Teriparatide (Forteo) is a synthetic fragment of parathyroid hormone approved by the FDA for postmenopausal osteoporosis in women at high fracture risk. In a landmark randomized trial, teriparatide reduced vertebral fracture risk by 65% compared to placebo in postmenopausal women with prior vertebral fractures. It is given by daily subcutaneous injection for a maximum of 24 months due to a historical concern about osteosarcoma seen in rat studies, though this has not been demonstrated in human populations.

Abaloparatide (Tymlos) is a related PTHrP analog with a similar fracture-reduction profile and the same 24-month treatment limit.

5. Peptides Used in Fertility and Reproductive Medicine

GnRH analogs are central to assisted reproductive technology (ART). GnRH agonists like leuprolide and GnRH antagonists like ganirelix (Antagon) and cetrorelix (Cetrotide) are used to prevent premature ovulation during IVF cycles. ASRM practice guidelines describe both protocols as standard of care for controlled ovarian stimulation.

Kisspeptin is an emerging peptide in fertility research. It sits upstream of GnRH and may eventually offer a more physiologic way to trigger ovulation, particularly in women with hypothalamic amenorrhea. Clinical trials are ongoing but no product is approved for this use.

Benefits by Life Stage

Reproductive Years (Ages Roughly 18-40)

During the menstrual cycle, estrogen and progesterone oscillate significantly, and these shifts affect peptide sensitivity. GLP-1 levels, for example, are slightly higher in the luteal phase. Women with PCOS, who have chronically elevated androgens and insulin resistance, show particular metabolic benefit from GLP-1 receptor agonists.

A meta-analysis in Fertility and Sterility found that GLP-1 receptor agonists in women with PCOS reduced fasting insulin, testosterone levels, and BMI compared to placebo or metformin alone. Menstrual regularity improved in several of the included trials. This is meaningful because anovulation is the primary driver of infertility in PCOS, and reducing hyperinsulinemia often restores ovulation.

Women using leuprolide for endometriosis or fibroids enter a medically induced hypoestrogenic state. That suppression is temporary and intentional, but it carries short-term side effects similar to menopause: hot flashes, bone density loss with prolonged use, and mood changes.

Trying to Conceive and Fertility Treatment

GnRH peptide analogs are standard tools in IVF. Nurses and reproductive endocrinologists teach patients to self-administer these subcutaneous injections as part of stimulation protocols. The timing and choice between agonist and antagonist protocols depends on your ovarian reserve, diagnosis, and clinic preference. Neither protocol is universally superior; outcomes depend on individual patient factors.

Perimenopause (Typically Ages 45-55, Sometimes Earlier)

Perimenopause is a period of profound peptide disruption. GnRH pulsatility increases, FSH rises, and the feedback loops that kept reproductive hormones stable for decades begin to lose their rhythm. At the same time, GLP-1 secretion may decline modestly with age, which partly explains why metabolic rate and satiety signaling shift in this life stage.

Women in perimenopause who use GLP-1 receptor agonists for weight management may find their results differ from what trials in younger populations showed. Most major GLP-1 trials enrolled predominantly premenopausal women or did not report outcomes stratified by menopausal status. This is a genuine evidence gap, and clinicians are currently extrapolating from general population data rather than perimenopause-specific trials. An honest assessment: we do not yet know whether the 14.9% average weight loss from semaglutide seen in STEP 1 applies equally to women in perimenopause or whether dose adjustments improve outcomes.

Bone-active peptides become relevant here too. Teriparatide and abaloparatide are options for women who have already experienced significant bone loss before or just after menopause, particularly if bisphosphonates are not tolerated.

Postmenopause

After menopause, estrogen decline changes the expression of multiple peptide receptors. The vaginal mucosa, which in premenopausal women benefits from local peptide signaling related to estrogen, becomes atrophic, contributing to genitourinary syndrome of menopause (GSM). While peptide therapies are not the standard treatment for GSM (vaginal estrogen is), ongoing research is examining oxytocin and other peptides as adjuncts.

Postmenopausal women represent the primary population for teriparatide. The FDA-approved prescribing information for Forteo specifies postmenopausal osteoporosis as the primary indication, with the 24-month cumulative lifetime limit noted clearly.

Cardiovascular peptide research is also relevant here. Natriuretic peptides (BNP, NT-proBNP) are diagnostic biomarkers for heart failure risk, which rises sharply after menopause. These are not treatments but reflect the broader role peptides play in monitoring women's long-term cardiovascular health.

Peptides in Women's Specific Conditions

PCOS

Polycystic ovary syndrome affects an estimated 8-13% of women of reproductive age, making it the most common endocrine disorder in this population. The condition involves insulin resistance, elevated androgens, and disrupted GnRH pulsatility. GLP-1 receptor agonists address the insulin-resistance component directly, and several studies suggest secondary reductions in androgen levels follow improved insulin sensitivity.

Endometriosis and Fibroids

Leuprolide and other GnRH agonists reduce estrogen to near-castrate levels, shrinking endometriotic implants and uterine fibroids. This is a proven, guideline-supported use, but the hypoestrogenic side effects limit treatment to 3-6 months without add-back hormone therapy. ACOG Practice Bulletin 114 supports GnRH agonists as a second-line medical management option for endometriosis.

Postmenopausal Osteoporosis

As described above, teriparatide and abaloparatide are anabolic agents, meaning they build new bone rather than simply slowing its loss. They are reserved for women with severe osteoporosis (T-score at or below negative 2.5 with a fragility fracture, or T-score at or below negative 3.0) who have not responded to or cannot tolerate bisphosphonates.

Female Pattern Hair Loss and Skin Aging

This is where the evidence gets thinner. Collagen peptide supplements have modest trial support for skin elasticity, as noted above. Several proprietary "hair peptide" products are marketed to women but rely on in-vitro data or small, industry-funded studies. No large independent RCT has established that topical or oral peptide supplements reliably reverse female pattern hair loss, though copper peptides used topically may have mild stimulatory effects on follicles.

Pregnancy, Lactation, and Contraception

This section is required reading if you are pregnant, breastfeeding, or trying to conceive while using any peptide-based therapy.

GLP-1 Receptor Agonists

Semaglutide, liraglutide, and tirzepatide are contraindicated in pregnancy. Animal studies showed dose-dependent fetal harm at doses below the human therapeutic range. The FDA prescribing information for Wegovy states that semaglutide should be discontinued at least 2 months before a planned pregnancy because of its long half-life (approximately 1 week) and the time required for drug washout. Women of reproductive age using GLP-1 receptor agonists should use reliable contraception. GLP-1 medications may improve ovulation in women with PCOS who were previously anovulatory, meaning unintended pregnancy becomes more likely as treatment begins.

Leuprolide and GnRH Analogs

Leuprolide is contraindicated in pregnancy. It can cause fetal harm and early pregnancy loss. Women using leuprolide for endometriosis or fibroids must use non-hormonal contraception during treatment. This is stated explicitly in the FDA labeling for Lupron Depot.

Teriparatide

Teriparatide is not recommended in pregnancy or lactation. Human data are absent; animal studies showed fetal skeletal abnormalities. Women of childbearing age prescribed teriparatide for severe early-onset osteoporosis should discuss contraception with their clinician.

Oxytocin

Oxytocin is used clinically in pregnancy for labor induction and in the immediate postpartum period. It is not a concern for pregnant women in these sanctioned obstetric uses; the concern arises with illicit or compounded oxytocin formulations used outside a medical setting, which carry unknown purity and dosing risks.

Collagen Peptide Supplements

No clear evidence of harm in pregnancy exists, but no adequate safety studies have been conducted. Standard guidance is to avoid non-essential supplements without direct clinician approval during pregnancy.

Lactation

GLP-1 receptor agonists: no human lactation data exist. Animal studies show transfer into milk. Women should not use semaglutide or tirzepatide while breastfeeding. Teriparatide: unknown lactation transfer; not recommended. Leuprolide: suppresses lactation and is not appropriate in breastfeeding women.

"Peptide Supplements" vs. FDA-Approved Peptide Drugs: An Honest Comparison

The supplement market has seized on peptide terminology to sell products with names like "BPC-157," "TB-500," "Ipamorelin," and "CJC-1295." These are often sold as research chemicals or compounded injections, and their use has grown sharply in the past five years, especially in functional medicine and biohacking spaces.

Here is an honest accounting of where the evidence stands:

BPC-157: Promising in rodent models for gut healing and tendon repair. A 2018 review in Current Pharmaceutical Design noted that human trials are entirely absent. FDA has issued warnings to compounding pharmacies manufacturing this substance.

TB-500 (Thymosin beta-4 fragment): No completed human RCTs. Animal data only.

Ipamorelin / CJC-1295: These are growth hormone secretagogues. They stimulate growth hormone release. No FDA-approved formulations exist. The long-term effects in women across different hormonal states are unknown.

Epithalon: A tetrapeptide claimed to extend telomeres and slow aging. Evidence in humans is essentially nonexistent.

The practical guidance: if a peptide is not FDA-approved and lacks human trial data, you are taking on unknown risk. "Natural" does not mean safe, especially during pregnancy, perimenopause, or if you have a hormone-sensitive condition like breast cancer or endometriosis.

Who This May Be Right For, and Who Should Be Cautious

Women who may benefit from FDA-approved peptide therapies:

• Women with obesity or type 2 diabetes who qualify for GLP-1 receptor agonists (BMI >30, or BMI >27 with a weight-related comorbidity)
• Women with PCOS and insulin resistance who have not achieved metabolic control with metformin alone
• Women with endometriosis or symptomatic fibroids managed by GnRH agonist therapy
• Postmenopausal women with severe osteoporosis and high fracture risk who need anabolic bone therapy
• Women undergoing IVF who require GnRH-based ovarian stimulation protocols

Women who should be cautious or avoid specific peptides:

• Anyone pregnant or actively trying to conceive (GLP-1 agonists, leuprolide, teriparatide are all contraindicated)
• Breastfeeding women (most peptide drugs lack lactation safety data)
• Women with a personal or strong family history of medullary thyroid carcinoma (semaglutide carries an FDA black-box warning for this risk, though it has not been demonstrated in humans)
• Women with hormone-sensitive cancers who are considering unregulated peptide products with unknown hormonal activity
• Women in perimenopause or postmenopause considering compounded "peptide protocols" that have not been studied in this life stage

What the Evidence Gap Looks Like in Practice

Women have been underrepresented in clinical trials for decades. The NIH Revitalization Act of 1993 required inclusion of women in federally funded trials, but a 2020 analysis in JAMA Internal Medicine found that women still make up a minority of participants in many cardiovascular and metabolic trials. For peptide therapies specifically, most foundational pharmacokinetic studies used male rodents or male human volunteers. This means that dosing recommendations, side-effect profiles, and efficacy estimates for many peptides are extrapolated to women rather than derived from women's data directly.

This matters most in two scenarios: perimenopause, where hormonal flux changes receptor dynamics in ways no current peptide trial has mapped systematically, and pregnancy, where almost every peptide therapy has a data gap that defaults to "avoid" rather than "confirmed safe."

When a clinician tells you a peptide is "safe for women," the honest follow-up question is: in which women, at which life stage, and based on what data? Demanding specificity is not distrust. It is good self-advocacy.